1
|
Gadomski S, Fielding C, García-García A, Korn C, Kapeni C, Ashraf S, Villadiego J, Toro RD, Domingues O, Skepper JN, Michel T, Zimmer J, Sendtner R, Dillon S, Poole KES, Holdsworth G, Sendtner M, Toledo-Aral JJ, De Bari C, McCaskie AW, Robey PG, Méndez-Ferrer S. A cholinergic neuroskeletal interface promotes bone formation during postnatal growth and exercise. Cell Stem Cell 2022; 29:528-544.e9. [PMID: 35276096 PMCID: PMC9033279 DOI: 10.1016/j.stem.2022.02.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2021] [Revised: 12/02/2021] [Accepted: 02/10/2022] [Indexed: 11/30/2022]
Abstract
The autonomic nervous system is a master regulator of homeostatic processes and stress responses. Sympathetic noradrenergic nerve fibers decrease bone mass, but the role of cholinergic signaling in bone has remained largely unknown. Here, we describe that early postnatally, a subset of sympathetic nerve fibers undergoes an interleukin-6 (IL-6)-induced cholinergic switch upon contacting the bone. A neurotrophic dependency mediated through GDNF-family receptor-α2 (GFRα2) and its ligand, neurturin (NRTN), is established between sympathetic cholinergic fibers and bone-embedded osteocytes, which require cholinergic innervation for their survival and connectivity. Bone-lining osteoprogenitors amplify and propagate cholinergic signals in the bone marrow (BM). Moderate exercise augments trabecular bone partly through an IL-6-dependent expansion of sympathetic cholinergic nerve fibers. Consequently, loss of cholinergic skeletal innervation reduces osteocyte survival and function, causing osteopenia and impaired skeletal adaptation to moderate exercise. These results uncover a cholinergic neuro-osteocyte interface that regulates skeletogenesis and skeletal turnover through bone-anabolic effects.
Collapse
Affiliation(s)
- Stephen Gadomski
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK; Skeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA; NIH Oxford-Cambridge Scholars Program in Partnership with Medical University of South Carolina, Charleston, SC 29425, USA
| | - Claire Fielding
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Andrés García-García
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Claudia Korn
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Chrysa Kapeni
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Sadaf Ashraf
- Arthritis and Regenerative Medicine Laboratory, Aberdeen Centre for Arthritis and Musculoskeletal Health, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
| | - Javier Villadiego
- Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, (CIBERNED), Madrid 28029, Spain
| | - Raquel Del Toro
- Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain
| | - Olivia Domingues
- Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur Alzette, Luxembourg
| | - Jeremy N Skepper
- Department of Physiology, Development, and Neuroscience, Cambridge Advanced Imaging Centre, University of Cambridge, Cambridge CB2 3DY, UK
| | - Tatiana Michel
- Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur Alzette, Luxembourg
| | - Jacques Zimmer
- Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur Alzette, Luxembourg
| | - Regine Sendtner
- Institute of Clinical Neurobiology, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany
| | - Scott Dillon
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK
| | - Kenneth E S Poole
- Cambridge NIHR Biomedical Research Centre, Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
| | | | - Michael Sendtner
- Institute of Clinical Neurobiology, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany
| | - Juan J Toledo-Aral
- Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, (CIBERNED), Madrid 28029, Spain
| | - Cosimo De Bari
- Arthritis and Regenerative Medicine Laboratory, Aberdeen Centre for Arthritis and Musculoskeletal Health, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
| | - Andrew W McCaskie
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Surgery, School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Pamela G Robey
- Skeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
| | - Simón Méndez-Ferrer
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK; Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain.
| |
Collapse
|
3
|
Hasan W, Smith PG. Nerve growth factor expression in parasympathetic neurons: regulation by sympathetic innervation. Eur J Neurosci 2000; 12:4391-7. [PMID: 11122349 DOI: 10.1046/j.0953-816x.2000.01353.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Interactions between sympathetic and parasympathetic nerves are important in regulating visceral target function. Sympathetic nerves are closely apposed to, and form functional synapses with, parasympathetic axons in many effector organs. The molecular mechanisms responsible for these structural and functional interactions are unknown. We explored the possibility that Nerve Growth Factor (NGF) synthesis by parasympathetic neurons provides a mechanism by which sympathetic-parasympathetic interactions are established. Parasympathetic pterygopalatine ganglia NGF-gene expression was examined by in situ hybridization and protein content assessed by immunohistochemistry. Under control conditions, NGF mRNA was present in approximately 60% and NGF protein was in 40% of pterygopalatine parasympathetic neurons. Peripheral parasympathetic axons identified by vesicular acetylcholine transporter-immunoreactivity also displayed NGF immunoreactivity. To determine if sympathetic innervation regulates parasympathetic NGF expression, the ipsilateral superior cervical ganglion was excised. Thirty days postsympathectomy, the numbers of NGF mRNA-positive neurons were decreased to 38% and NGF immunoreactive neurons to 15%. This reduction was due to a loss of sympathetic nerve impulse activity, as similar reductions were achieved when superior cervical ganglia were deprived of preganglionic afferent input for 40 days. These findings provide evidence that normally NGF is synthesized by parasympathetic neurons and transported anterogradely to fibre terminals, where it may be available to sympathetic axons. Parasympathetic NGF expression, in turn, is augmented by impulse activity within (and presumably transmitter release from) sympathetic axons. It is suggested that parasympathetic NGF synthesis and its modulation by sympathetic innervation provides a molecular basis for establishment and maintenance of autonomic axo-axonal synaptic interactions.
Collapse
Affiliation(s)
- W Hasan
- Department of Molecular and Integrative Physiology, and; R.L. Smith Mental Retardation Research Center, University of Kansas Medical Center, Kansas City, 3901 Rainbow Blvd, Kansas 66160-7401, USA
| | | |
Collapse
|
4
|
Drijfhout WJ, Grol CJ, Westerink BH. Parasympathetic inhibition of pineal indole metabolism by prejunctional modulation of noradrenaline release. Eur J Pharmacol 1996; 308:117-24. [PMID: 8840122 DOI: 10.1016/0014-2999(96)00283-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The role of the parasympathetic nervous system in rat pineal indole metabolism was investigated by transpineal in vivo microdialysis. On-line coupling to a high performance liquid chromatography system with fluorescence detection (HPLC-FD) allowed simultaneous analysis of three major indolic compounds from the pineal, i.e. serotonin, N-acetylserotonin and melatonin. Infusion of the muscarinic receptor agonists, carbachol and oxotremorine, during the dark period resulted in a marked decrease of melatonin release. This effect was suggested to be mediated by a decrease in N-acetyltransferase activity, since a similar decrease was seen in N-acetylserotonin release, while serotonin levels increased simultaneously. Nicotine did show a very slight effect on the three indoles under these circumstances. Neostigmine failed to influence pineal indole metabolism, indicating that the endogenous tonus of acetylcholine release is either absent or extremely low in the middle of the dark period. The involvement of sympathetic innervation in the muscarinic effects was investigated by measurement of noradrenaline release from the pineal by sensitive off-line HPLC-FD analysis of noradrenaline in the dialysates. Carbachol markedly decreased the noradrenaline input during the infusion. Noradrenaline release returned to baseline values immediately after infusion with carbachol. These data suggest that the in vivo inhibitory effect of muscarinic receptor agonists on pineal melatonin production is mediated by presynaptic muscarinic receptors, located on the sympathetic nerve endings. This prejunctional inhibition of noradrenaline release causes a reduced induction of N-acetyltransferase activity, resulting in decreased melatonin release.
Collapse
Affiliation(s)
- W J Drijfhout
- University Centre for Pharmacy, Department of Medicinal Chemistry, Groningen, Netherlands.
| | | | | |
Collapse
|
5
|
Brunn G, Wessler I, Anderson GP, Maclagan J, Racké K. Beta-adrenoceptor-mediated facilitation of endogenous noradrenaline release from rat isolated trachea. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1994; 350:459-63. [PMID: 7870184 DOI: 10.1007/bf00173014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Overflow of endogenous noradrenaline from rat isolated trachea was evoked by electrical field stimulation (3 Hz, 540 pulses) in the presence of yohimbine, desipramine and tyrosine. Isoprenaline 100 nmol/l increased the evoked overflow of noradrenaline by about 65%. This effect was antagonized by propranolol (100 nmol/l) and the beta 2-selective adrenoceptor antagonist ICI 118,551 (100 nmol/l), but not by the beta 1-selective adrenoceptor antagonist CGP 20712 A (100 nmol/l). The beta 2-selective adrenoceptor agonist formoterol (1-100 nmol/l) also facilitated the evoked overflow of noradrenaline, but maximally by only about 25% at 10 nmol/l, i.e. formoterol behaved as a partial agonist at these facilitatory beta-adrenoceptor. This assumption is also supported by the observation that formoterol (10 nmol/l) acted as antagonist against isoprenaline (100 nmol/l). Mechanical removal of the mucosa resulted in a 30% decrease in tissue noradrenaline and a 55% reduction of the evoked overflow of noradrenaline. In mucosa-denuded preparations isoprenaline failed to facilitate noradrenaline overflow. In the presence of indomethacin (3 mumol/l) the evoked overflow of noradrenaline from mucosa containing preparations was increased by about 50%, but isoprenaline still further facilitated the evoked noradrenaline overflow by about 40%. In conclusion, the overflow of noradrenaline in the rat trachea is facilitated via beta 2-adrenoceptors, an effect which requires an intact airway mucosa.
Collapse
Affiliation(s)
- G Brunn
- Department of Pharmacology, University of Frankfurt, Germany
| | | | | | | | | |
Collapse
|
8
|
Racké K, Brunn G, Elsner M, Wessler I. Effects of indomethacin on muscarinic inhibition of endogenous noradrenaline release from rat isolated trachea. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1993; 348:21-7. [PMID: 8377837 DOI: 10.1007/bf00168532] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The release of endogenous noradrenaline from rat isolated tracheae was evoked by electrical field stimulation (3 Hz, 540 pulses) in the presence of yohimbine, desipramine and tyrosine. The muscarine receptor agonist oxotremorine concentration-dependently inhibited the evoked release of noradrenaline by 95% at 1 mumol/l, EC50 values in two series of experiments 41 and 57 nmol/l, respectively. The effect of oxotremorine was antagonized by the non-selective muscarine receptor antagonist scopolamine (10-1000 nmol/l) in a manner suggesting a simple competitive interaction (slope of Schild plot -0.94; pA2 value 8.88). However, the M2 selective muscarine receptor antagonist methoctramine (0.1-10 mumol/l) affected the action of oxotremorine in a manner suggesting a complex interaction (slope of Schild plot -0.47). Addition of indomethacin (3 mumol/l) caused an increase of the evoked release of noradrenaline by 45% and low concentrations of oxotremorine (0.01 and 0.1 mumol/l, but not 1 mumol/l) became less effective resulting in a slight shift to the right of the concentration response curve (EC50 169 nmol/l). Moreover, in the presence of indomethacin methoctramine (0.1-10 mumol/l) antagonized the effects of oxotremorine in a manner suggesting a simple competitive interaction (slope of Schild plot -0.93, pA2 value 7.61). In the presence of indomethacin, the concentration response curve of oxotremorine was only slightly shifted to the right in the presence of the M1 receptor selective antagonist pirenzepine (1 mumol/l, -log KB 6.1) and not significantly affected by the M3 receptor selective antagonist p-fluoro-hexahydrosiladifenidol (1 mumol/l). In conclusion, the release of noradrenaline in the rat trachea is inhibited via presynaptic muscarine heteroreceptors of the M2 subtype.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K Racké
- Department of Pharmacology, University of Frankfurt, Germany
| | | | | | | |
Collapse
|
11
|
Pendry YD, Maclagan J. Evidence for inhibition of sympathetic neurotransmission by endogenously released acetylcholine in the guinea-pig trachea. Br J Pharmacol 1991; 104:817-22. [PMID: 1667287 PMCID: PMC1908860 DOI: 10.1111/j.1476-5381.1991.tb12512.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
1. Interactions between pulmonary cholinergic and noradrenergic nerves were studied in the innervated tracheal tube preparation isolated from guinea-pigs anaesthetized with urethane. Relaxations of the trachealis smooth muscle in response to postganglionic stimulation of the sympathetic nerve were recorded as decreases in the intraluminal pressure of the tracheal tube after the pressure had been raised with the stable thromboxane-mimetic, U46619. In contrast, contractions following preganglionic stimulation of the vagal nerve trunk were recorded as increases in intraluminal pressure. 2. In approximately half of the preparations studied, concurrent stimulation of of the vagal nerve trunk the vagal nerve trunk inhibited relaxation responses elicited by stimulation of the sympathetic nerves. The vagi were stimulated at parameters which caused no change in intraluminal pressure, excluding the involvement of postjunctional mechanisms. 3. The effect of simultaneous stimulation of the sympathetic nerve trunk was studied on contractile responses evoked by preganglionic stimulation of the vagus nerve. In 80% of the preparations tested the vagal responses were inhibited. This inhibitory effect of sympathetic nerve stimulation was antagonized by propranolol. 4. The potassium channel agonist, cromakalim, endothelins 1 and 3 and the neuropeptides, vasoactive intestinal peptide, neurokinin A and substance P, did not significantly modulate sympathetic nerve-induced relaxations. 5. The anticholinesterase drug, physostigmine, induced a concentration-dependent increase in the intraluminal pressure of the tracheal tube and potentiated the postjunctional action of exogenously applied acetylcholine to contract the guinea-pig trachealis muscle. In the presence of higher concentrations of physostigmine both vagally-induced contractions and sympathetic nerve-induced relaxations were reduced. Atropine blocked both the inhibitory effect of physostigmine on sympathetic relaxations and its postjunctional contractile action on the trachealis smooth muscle.6. It is concluded that, in the guinea-pig trachea, acetylcholine released endogenously from pulmonary parasympathetic nerves, either by anticholinesterase drugs or in response to nerve stimulation, can inhibit transmission in the adjacent sympathetic nerves via activation of prejunctional muscarinic heteroreceptors, probably of the M3 subtype.
Collapse
Affiliation(s)
- Y D Pendry
- Academic Department of Pharmacology, Royal Free Hospital School of Medicine, London
| | | |
Collapse
|